These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3757789)

  • 41. Visual compatibility of ceftizoxime sodium in four electrolyte injections.
    Swenson E; Gooch WM; Higbee MD
    Am J Hosp Pharm; 1986 Sep; 43(9):2242-4. PubMed ID: 3766586
    [No Abstract]   [Full Text] [Related]  

  • 42. Visual compatibility of perphenazine with various antimicrobials during simulated Y-site injection.
    Gasca M; Fanikos J; Souney PF
    Am J Hosp Pharm; 1987 Mar; 44(3):574-5. PubMed ID: 3565416
    [No Abstract]   [Full Text] [Related]  

  • 43. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs.
    Hasegawa GR; Eder JF
    Am J Hosp Pharm; 1984 Jul; 41(7):1379-80. PubMed ID: 6465154
    [No Abstract]   [Full Text] [Related]  

  • 44. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
    Marquardt ED; Lam SS
    Am J Hosp Pharm; 1994 Mar; 51(6):811-2. PubMed ID: 8010323
    [No Abstract]   [Full Text] [Related]  

  • 45. Visual compatibility of ranitidine hydrochloride with commonly used critical-care medications.
    Chilvers MR; Lysne JM
    Am J Hosp Pharm; 1989 Oct; 46(10):2057-8. PubMed ID: 2816963
    [No Abstract]   [Full Text] [Related]  

  • 46. Visual compatibility of cimetidine hydrochloride with common preoperative injectable medications.
    Souney PF; Solomon MA; Stancher D
    Am J Hosp Pharm; 1984 Sep; 41(9):1840-1. PubMed ID: 6496520
    [No Abstract]   [Full Text] [Related]  

  • 47. Compatibilities and stabilities of i.v. preparations.
    Garabedian-Ruffalo SM; Ruffalo RL
    Crit Care Nurse; 1989 Feb; 9(2):81-5. PubMed ID: 2582799
    [No Abstract]   [Full Text] [Related]  

  • 48. A review of paclitaxel (Taxol) administration, stability, and compatibility issues.
    Boyle DA; Goldspiel BR
    Clin J Oncol Nurs; 1998 Oct; 2(4):141-5. PubMed ID: 10232160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Guidelines for administering i.v. drugs.
    Wiggins MS; Sesin P
    Nursing; 1990 Apr; 20(4):145-52. PubMed ID: 2320296
    [No Abstract]   [Full Text] [Related]  

  • 50. Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
    den Brok MW; Nuijen B; Harms R; Buluran JN; Harvey MD; Grieshaber CK; Beijnen JH
    J Oncol Pharm Pract; 2005 Mar; 11(1):13-9. PubMed ID: 16460599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravenous drug compatibility.
    DeMonaco HJ
    Crit Care Med; 1990 Aug; 18(8):896. PubMed ID: 2379406
    [No Abstract]   [Full Text] [Related]  

  • 52. Physical compatibility of nine drugs in various intravenous solutions.
    Dixon FW; Weshalek J
    Am J Hosp Pharm; 1972 Oct; 29(10):822-3. PubMed ID: 5075118
    [No Abstract]   [Full Text] [Related]  

  • 53. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part 2.
    Allen LV; Stiles ML
    Am J Hosp Pharm; 1981 Mar; 38(3):380-1. PubMed ID: 7223755
    [No Abstract]   [Full Text] [Related]  

  • 54. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
    Trissel LA; Williams KY; Gilbert DL
    J Am Pharm Assoc (Wash); 2000; 40(4):515-9. PubMed ID: 10932461
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The availability of antibiotics in combination with other additives in intravenous solutions.
    Dancey JW; Carew DP
    Am J Hosp Pharm; 1966 Oct; 23(10):543-51. PubMed ID: 5915776
    [No Abstract]   [Full Text] [Related]  

  • 56. [Drug compatibility and incompatibility in infusion solutions].
    Viering HD
    Infusionstherapie (1973); 1973 Oct; 1(1):74. PubMed ID: 4806247
    [No Abstract]   [Full Text] [Related]  

  • 57. Drug incompatibility from the standpoint of the intravenous route of drug administration.
    Williams JT
    Hosp Manage; 1968 Jan; 105(1):38 passim. PubMed ID: 5634868
    [No Abstract]   [Full Text] [Related]  

  • 58. Compatibility and stability of clindamycin phosphate with intravenous fluids.
    Porter WR; Johnson CA; Cohon MS; Gillespie W
    Am J Hosp Pharm; 1983 Jan; 40(1):91-4. PubMed ID: 6823996
    [No Abstract]   [Full Text] [Related]  

  • 59. Solid-state compatibility studies using a high-throughput and automated forced degradation system.
    Wakasawa T; Sano K; Hirakura Y; Toyo'oka T; Kitamura S
    Int J Pharm; 2008 May; 355(1-2):164-73. PubMed ID: 18215480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug additive compatibility--a manufacturer's concern.
    Nedich RL
    Bull Parenter Drug Assoc; 1973; 27(5):228-33. PubMed ID: 4201030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.